{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:09Z","timestamp":1790889909236,"version":"4.1.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Receptor tyrosine kinase\u2013like orphan receptor (ROR)1 is overexpressed in some hematological cancers but has low expression in normal tissues, making it a potential therapeutic target. We investigated this therapeutic potential in childhood B-cell precursor (BCP) and T-cell acute lymphoblastic leukemia (T-ALL) cases. The proportion of ROR1+ cells was significantly higher in T-ALL (median, 13.8%; range, 2.9%-87%) than BCP-ALL (6%, 0.3%-83%, P = .02). Antigen density was also lower in BCP-ALL (median, 1027; range, 876-2588) compared to T-ALL (1089, 865-1527). In leukemia propagating cells (LPCs), ROR1 levels were highest in CD34\u2013\/CD19+ and CD34\u2013\/CD7+ subpopulations. Notably, ROR1+ LPC, in both BCP-ALL and T-ALL, survived induction therapy and their numbers increased post treatment. Subsequently, ROR1 bispecific T-cell engagers (Teng) were tested on primary cases in vitro and in vivo. Addition of ROR1 Teng in vitro reduced ALL survival to 44% in BCP-ALL and 58% in T-ALL, compared to T cells alone (94% and 84%, respectively; P \u2264 .01). When NOD.Cg-PrkdcscidIl2r\u03b3tm1Wjl\/SzJ mice engrafted with primary leukemia were treated with ROR1 Teng, disease burden was reduced by up to 520-fold (from 15.6% to 0.03%) in ROR1+ cells and 68-fold (58% to 0.9%) in CD19+ cells in BCP-ALL. In T-ALL cases, there was a fourfold reduction (from 1.2% to 0.3%) in ROR1+ and 2.3-fold (from 83.7% to 36.7%) in CD7+ levels. This resistance of ROR1+ cells to current therapies makes it an important target. Moreover, as ROR1 Teng were at least comparable to CD19 Teng in vivo, they could be considered for the treatment of refractory BCP-ALL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013814","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T18:00:50Z","timestamp":1744826450000},"page":"3190-3201","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Expression and treatment of ROR1+ cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"9","author":[{"given":"Paraskevi","family":"Diamanti","sequence":"first","affiliation":[{"name":"1Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant Filton, Filton, United Kingdom"},{"name":"2School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan K.","family":"Bailey","sequence":"additional","affiliation":[{"name":"2School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obinna E.","family":"Iheanacho","sequence":"additional","affiliation":[{"name":"2School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1844-3531","authenticated-orcid":false,"given":"John P.","family":"Moppett","sequence":"additional","affiliation":[{"name":"3Department of Haematology, Bristol Royal Hospital for Children, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit C.","family":"Nathwani","sequence":"additional","affiliation":[{"name":"4NovalGen Ltd, London, United Kingdom"},{"name":"5Department of Haematology, University College London, London, United Kingdom"},{"name":"6Department of Haematology, Royal Free Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5156","authenticated-orcid":false,"given":"Allison","family":"Blair","sequence":"additional","affiliation":[{"name":"1Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant Filton, Filton, United Kingdom"},{"name":"2School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"6","key":"2025070810565240300_bib1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of Children's Oncology Group trial AALL0331","volume":"38","author":"Maloney","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025070810565240300_bib2","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.3390\/ijms22094502","article-title":"The new therapeutic strategies in pediatric T-cell acute lymphoblastic leukemia","volume":"22","author":"Lato","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2025070810565240300_bib3","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41375-022-01540-1","article-title":"Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study","volume":"36","author":"Jensen","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2025070810565240300_bib4","doi-asserted-by":"crossref","first-page":"e26909","DOI":"10.1002\/pbc.26909","article-title":"Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Oskarsson","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2025070810565240300_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bjh.16773","article-title":"Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors","volume":"192","author":"Diamanti","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"2025070810565240300_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","article-title":"Immunotherapy in pediatric acute lymphoblastic leukemia","volume":"38","author":"Inaba","year":"2019","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"2025070810565240300_bib7","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"9","key":"2025070810565240300_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2025070810565240300_bib9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"2025070810565240300_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.23.01392","article-title":"Blinatumomab for first-line treatment of children and young persons with B-ALL","volume":"42","author":"Hodder","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025070810565240300_bib11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"2025070810565240300_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2025070810565240300_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/leu.2011.212","article-title":"Comparison of childhood leukemia initiating cell populations in NOD\/SCID and NSG mice","volume":"26","author":"Diamanti","year":"2012","journal-title":"Leukemia"},{"key":"2025070810565240300_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"issue":"18","key":"2025070810565240300_bib15","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/bloodadvances.2020003534","article-title":"Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy","volume":"5","author":"Diamanti","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025070810565240300_bib16","doi-asserted-by":"crossref","first-page":"e0165210","DOI":"10.1371\/journal.pone.0165210","article-title":"Investigating CD99 expression in leukemia propagating cells in childhood T cell acute lymphoblastic leukemia","volume":"11","author":"Cox","year":"2016","journal-title":"PLoS One"},{"key":"2025070810565240300_bib17","doi-asserted-by":"crossref","first-page":"680834","DOI":"10.3389\/fonc.2021.680834","article-title":"Tyrosine kinase ROR1 as a target for anti-cancer therapies","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"2025070810565240300_bib18","doi-asserted-by":"crossref","first-page":"25168657211064232","DOI":"10.1177\/25168657211064232","article-title":"Roles of Wnt signaling pathway and ROR2 receptor in embryonic development: an update review article","volume":"15","author":"Guo","year":"2022","journal-title":"Epigenet Insights"},{"issue":"25","key":"2025070810565240300_bib19","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2025070810565240300_bib20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/10428190802124000","article-title":"Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia","volume":"49","author":"Shabani","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025070810565240300_bib21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1186\/s12885-020-07587-6","article-title":"Functional and clinical significance of ROR1 in lung adenocarcinoma","volume":"20","author":"Schiavone","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"2025070810565240300_bib22","doi-asserted-by":"crossref","first-page":"e31127","DOI":"10.1371\/journal.pone.0031127","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"2025070810565240300_bib23","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.leukres.2011.06.021","article-title":"ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia","volume":"35","author":"Broome","year":"2011","journal-title":"Leuk Res"},{"issue":"12","key":"2025070810565240300_bib24","doi-asserted-by":"crossref","first-page":"e52655","DOI":"10.1371\/journal.pone.0052655","article-title":"Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies","volume":"7","author":"Dave","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"2025070810565240300_bib25","doi-asserted-by":"crossref","first-page":"e21018","DOI":"10.1371\/journal.pone.0021018","article-title":"Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"2025070810565240300_bib26","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/leu.2011.362","article-title":"Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells","volume":"26","author":"Daneshmanesh","year":"2012","journal-title":"Leukemia"},{"issue":"suppl 0","key":"2025070810565240300_bib27","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.clml.2015.02.010","article-title":"Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1","volume":"15","author":"Choi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2025070810565240300_bib28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2025070810565240300_bib29","doi-asserted-by":"crossref","first-page":"e1326437","DOI":"10.1080\/2162402X.2017.1326437","article-title":"An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors","volume":"6","author":"Gohil","year":"2017","journal-title":"Oncoimmunology"},{"issue":"2","key":"2025070810565240300_bib30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.15911","article-title":"Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia","volume":"186","author":"Gohil","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"2025070810565240300_bib31","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2012-08-448852","article-title":"Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia","volume":"121","author":"Diamanti","year":"2013","journal-title":"Blood"},{"key":"2025070810565240300_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2019.07.026","article-title":"Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial","volume":"120","author":"Jackson","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"2025070810565240300_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.13847","article-title":"Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003","volume":"172","author":"Hough","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2025070810565240300_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"suppl 15","key":"2025070810565240300_bib35","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2021.39.15_suppl.7549","article-title":"NVG-111, a novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma","volume":"39","author":"Granger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025070810565240300_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2023-188607","article-title":"Time limited exposure to a ROR1 targeting bispecific T cell engager (NVG-111) leads to durable responses in subjects with relapsed refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)","volume":"142","author":"Townsend","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025070810565240300_bib37","article-title":"Antigen density determines the efficacy of chimeric antigen receptor (CAR) re-targeted T-cells [abstract]","volume":"4","author":"Davies","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2025070810565240300_bib38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"issue":"3","key":"2025070810565240300_bib39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti\u2013CD20-CD28-CD3 \u03b6 chimeric antigen receptor\u2013modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J Immunol"},{"issue":"4","key":"2025070810565240300_bib40","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1073\/pnas.1816262116","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025070810565240300_bib41","first-page":"4316","article-title":"A ROR1 bispecific T cell engager for the treatment of chronic lymphocytic leukaemia demonstrates enhanced function following ibrutinib treatment","volume":"130","author":"Gohil","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2025070810565240300_bib42","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2025070810565240300_bib43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025070810565240300_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"17","key":"2025070810565240300_bib45","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025070810565240300_bib46","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"2025070810565240300_bib47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2025070810565240300_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3190\/2382223\/blooda_adv-2024-013814-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3190\/2382223\/blooda_adv-2024-013814-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T14:57:01Z","timestamp":1751986621000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/13\/3190\/536728\/Expression-and-treatment-of-ROR1-cells-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":48,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013814","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,8]]},"published":{"date-parts":[[2025,6,26]]}}}